Navigation Links
Functional Differences In Estrogen Receptor Could Be A Therapeutic Target

Differences in a newly uncovered estrogen receptor could turn out to be an important therapeutic target besides playing a vital role in signaling //other target tissues like uterus and prostate tissues.

These new findings could significantly advance the understanding of the effects of estrogen in breast cancer and point the way towards new and potentially more effective treatments of the disease.

The new study was published this week in an advanced online edition of the Proceedings of the National Academy of Sciences.

Estrogen has long been linked to the development of breast cancer, both through the stimulation of breast cell growth, which can lead to mutation, and through estrogen metabolism, which can interfere with apoptosis and DNA repair. Estrogen receptors mediate the majority of the actions of estrogen, including the metastatic growth of breast cancer cells, and are an important marker in therapy; readable levels of estrogen receptor proteins are expressed in a large portion of human breast cells.

Professor Thomas F. Deuel, M.D., a Scripps Research scientist who participated in the study said, 'The estrogen and anti-estrogen signaling pathways mediated by this new receptor could explain why some breast cancers grow worse or become resistant to anti-estrogen therapy, specifically the drug tamoxifen, which blocks estrogen signaled responses through ER-a66 in breast tissue.' According to the National Cancer Institute, anti-estrogen therapy is most often used in postmenopausal women whose tumors grow in response to the hormone.

'Worldwide, breast cancer is the most common form of cancer in women and the second most common cause of death for women in the United States,' Deuel said. 'The toll in suffering and mortality is especially devastating because breast cancer strikes women at a time in their lives when they are most productive and they are busy with children and raising a family. This continues des
'"/>




Page: 1 2 3

Related medicine news :

1. Functional foods reduce cholesterol
2. Shy Bladder Syndrome: A Social Phobia Or Functional Disorder Of Micturition?
3. Bio-Functional Garments That Could Revolutionize Fashion Industry
4. Functional Taste Cells Cultured In Vitro
5. Patents: Appellate Board Becomes Functional
6. Differences in brain pattern among liars and cheats in comparison to honest people
7. Ethnic Differences in Healthcare
8. Ethnic Variations in Hormone Levels May Cause Differences in Breast Cancer Risk
9. Wide Differences between NHS staff and ministers
10. Differences Between BP Medicines and Newly-Diagnosed Diabetes Identified
11. Diminishing Differences and Empowering Eves
Post Your Comments:
(Date:11/21/2008)... MediConnect CEO, Amy Rees And...ary of Health, Michael Leavitt, in the 2008 Nation... Salt Lake City (Vocus) November 20...invited to participate with U.S. Secretary of Heal...n Personalized Health Care. The Summit brings tog...
(Date:11/21/2008)... Texas Monthly Magazine announ...r Dentist" award given to elite dentists in T... once again nominated a top practitioner in the ar... Austin, TX (PRWEB) November 21, 2008-- Dr. Mich...ted as a "Texas Monthly Super Dentist" f...
(Date:11/20/2008)...g-term use of a macrolide antibiotic may reduce th...rate to severe chronic obstructive pulmonary disea... London-based study. , "Our results show a sign...cing exacerbation frequency and severity with mode...er, Terence A. R. Seemungal, Ph.D., and Jadwiga We...
(Date:11/20/2008)...YORK Nov. 19, 2008 The American Cancer Society ... and largest non-governmental funder of cancer res...r, the Medal of Honor, to four Americans who have ...t cancer. This year,s winners, who will receive th...r Society,s annual meeting in New York City, are: ...
Breaking Medicine News(10 mins):Health News:MediConnect Participates in 2008 National Health Summit 2Health News:Texas Super Dentist Awards Announced--Dr. Michael McCarty From Austin Smiles Is Awarded For The Third Year In A Row 2Health News:Long-term antibiotics reduce COPD exacerbations, raise questions 2Health News:Long-term antibiotics reduce COPD exacerbations, raise questions 3Health News:Scientists honored for contributions to cancer fight 2Health News:Scientists honored for contributions to cancer fight 3Health News:Scientists honored for contributions to cancer fight 4Health News:Scientists honored for contributions to cancer fight 5
... UK are demanding complete overhauling of, the Hum...following a judicial rap it has received. The H...egulator had unlawfully obtained warrants to searc...umentary. The Human Fertilisation and Embryology ...
... Klass has followed in the footsteps of actress De...year-old I'm A Celebrity star, wearing only her en...d for Glamour magazine's British edition. "You do...ly or my bum look big'. You just think, 'Wow, I'm ...
... Friday called for taking advantage of the benefit...tele-radiology to help the needy in rural areas in...a visit to the digital radiology centre at Electro...CIL), which is working towards providing low cost ...
...trict are grappling to fight against a deadly vira...ed at least 30 children in the past five months. D... Medical College, said that the hospital run by th...ents since January out of whom 30 children have so...
Other Medicine News:Health News:UK Doctors Demand Overhauling of Fertility Regulatory Authority 2
(Date:11/19/2008)...tical significance , , ISELIN, N.J., Nov. 1...Nasdaq: PARS ) today announced results from its ...n (NE) drug delivery technology formulated with 3%...enter, randomized, double-blinded, placebo-control... Company,s 3% Diclofenac Diethanolamine NanoEmulsi...
(Date:11/19/2008)... -- Biotech scientists increasingly are applying g...ter understand the effects of novel drug candidate...Engineering & Biotechnology News ( GEN ). The...compound,s mechanism of action and eventually deve...g to the November 15 issue of GEN . ( http://www....
(Date:11/19/2008)... , , MONTVALE, N.J., Nov. 19 /PRNewswire-Fi... MEMY ) today announced that it has achieved the ... 3454, its lead alpha-7 nicotinic receptor agonist...renia (CIAS). The Company has randomized 212 pati...on payment from its partner Roche. Memory Pharmac...
(Date:11/18/2008)...more, make a donation or send a Christmas Seals e-...Newswire/ -- Millions will receive Christmas Seals...Lung Association. These decorative holiday stamps ... back to 1907 when the Lung Association led effort...icans alive today have no vivid memories of how wi...
Breaking Medicine Technology:Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Tick borne encephalitis virus reveals its access code 5456 1A dinosaur dance floor 5453 1A dinosaur dance floor 5453 2A dinosaur dance floor 5453 3A dinosaur dance floor 5453 4A dinosaur dance floor 5453 5Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC IDSA 3308 1Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC IDSA 3308 2Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC IDSA 3308 3Bird flu vaccine protects people and pets 5451 1Bird flu vaccine protects people and pets 5451 2
... Minimal Weight Change Reported Unlike What Is Com...2007 – Novo Nordisk today announced,results ...y and,efficacy of insulin Levemir® (insulin de...e 2 diabetes were able to adjust,their own dosage ...sugar, comparable to dosing adjusted by their prim...
...CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - New data ...ican Diabetes Association,(ADA) 67th Annual Scient...apy with Januvia(TM) (sitagliptin) and metformin,d...beta cell,function in patients with type 2 diabete...the ability of the body to produce,insulin, a horm...
Other Medicine Technology:New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 2New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 3New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 4New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 5An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 2An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 3An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 4An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 5An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 6An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 7An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 8An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 9An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 10An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 11An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 12An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 13An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 14An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 15An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 16An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 17An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 18An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 19An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 20An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 21An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 22An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 23An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 24An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 25An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 26An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 27An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 28An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 29An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 30An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 31An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 32
1000 L, Racked, 96 tips/rack, clear Recommended for 500 and 1000 L pipettes.
300 L, Racked, 96 tips/rack Recommended for 250 and 300 L pipettes.
RNase-free Tips
MBP's 200 ul large orifice tip is perfect for handling fragile cells, viscous samples and genomic.
Medicine Products: